Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 5/20 | 0.46 |
| ▸ | PPARA | Q07869 | 2/20 | 0.41 |
| ▸ | REN | P00797 | 2/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 6/20 | 0.38 |
| ▸ | CTSL | P07711 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | CTSB | P07858 | 1/20 | 0.37 |
| ▸ | KLK7 | P49862 | 2/20 | 0.37 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.37 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.36 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.36 |
| ▸ | CAPN2 | P17655 | 1/20 | 0.36 |
| ▸ | SYK | P43405 | 1/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4348011 | 1.00 | CTSS (0.46) | CTSSPPARARENPPARGCTSK | |
| SCHEMBL4356049 | 0.91 | CTSS (0.39) | CTSSPPARA | |
| SCHEMBL4356052 | 0.91 | CTSS (0.39) | CTSSPPARA | |
| SCHEMBL13613765 | 0.82 | SYK (0.46) | CTSSCTSKCTSLCTSBSYK | |
| SCHEMBL4344615 | 0.79 | PTPN1 (0.36) | CTSSPPARACTSKCTSL | |
| SCHEMBL13613768 | 0.79 | PTPN1 (0.36) | CTSSCTSKCTSL | |
| SCHEMBL4350950 | 0.77 | SYK (0.46) | CTSSCTSKCTSLCTSBSYK | |
| SCHEMBL16318175 | 0.74 | CAPN1 (0.46) | CTSSCTSKCTSLCTSBCAPN1 | |
| SCHEMBL13613734 | 0.73 | SYK (0.44) | CTSSCTSKCTSLCTSBSYK | |
| SCHEMBL8697793 | 0.71 | PPARA (0.65) | CTSSPPARARENPPARGCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275727-A1 | Peptide turn mimetics | MIMETICA PTY LIMITED (AU) | 2009-11-05 | — | — | US | disclosed |
| US-20090275727-A1 | Peptide turn mimetics | MIMETICA PTY LIMITED (AU) | 2009-11-05 | — | — | US | disclosed |
| US-20090275727-A1 | Peptide turn mimetics | MIMETICA PTY LIMITED (AU) | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275727-A1 | Peptide turn mimetics | IAPP, GLP1R, VIP | CTSS 1601/4885PPARA 4156/4885REN 791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.